# Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer

> **NCT00101907** · PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 41 (actual)

## Conditions studied

- Lung Cancer
- Pancreatic Cancer
- Esophageal Cancer

## Interventions

- **DRUG:** AMG 706
- **BIOLOGICAL:** Panitumumab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00101907
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-12
- **Primary completion:** 2007-06
- **Final completion:** 2008-04
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Study terminated per recommendation of Data Review Team
- **Last updated:** 2014-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00101907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00101907, "Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00101907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*